跳至主要内容
临床试验/JPRN-UMIN000009510
JPRN-UMIN000009510已完成2 期

A Phase II/III Randomized multicenter Trial of Intersphincteric resection (ISR) with or without Preoperative Chemotherapy for very low-lying Rectal Cancer - Neo-adjuvant chemotherapy for Intersphincteric resection (ISR) in Low Rectal Cancers NAIR. Study

ational Cancer Center Hospital East0 个研究点目标入组 200 人开始时间: 2012年12月20日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 75years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) Patients with request of abdominoperineal resection (APR) 2) Patients with impossibility for ISR 3) Patients with poor anal function preoperatively 4) Synchronous or metachronous (within 5 years) malignancies other than carcinoma in site or mucosal carcinoma 5) Patients with serious diseases as follows i. Uncontrollable diabetes mellitus ii. Uncontrollable hypertension iii. Interstitial pneumonia, pulmonary fibrosis, or severe emphysema 6) Chronic active hepatitis type B. Positive for HCV 7) Episodes of blood transfusion within the post 14 days 8) Patients with severe mental disease 9) Cannot agree on this study 10) Unsuitable patients for this study

研究者

发起方
ational Cancer Center Hospital East

相似试验

已完成
不适用
A Phase II/III Randomized multicenter Trial of Intersphincteric resection (ISR) with or without Preoperative Chemotherapy for very low-lying Rectal Cancer(UMIN9510) -Additional study: How to predict the chemotherapy responseVery Low Rectal Cancer
JPRN-UMIN000030226ational Defense Medical College200
进行中(未招募)
2 期
eo-adjuvant chemotherapy for Intersphincteric resection (ISR) in Low Rectal CancersRectal Cancerrectal cancer
JPRN-jRCTs031180278Ito Masaaki128
进行中(未招募)
1 期
A multi-centre 3-arm randomized phase II trial of BIBF 1120 versus BIBW 2992 versus sequential administration of BIBF 1120 and BIBW 2992 in patients with hormone-resistant prostate cancerChemo-naive hormone refractory prostate cancer
EUCTR2005-005249-21-GBBoehringer Ingelheim Ltd.105
进行中(未招募)
不适用
A multicenter randomized phase II Trial assessing the activity of Gemcitabine - Oxaliplatin chemotherapy alone or in combination with Cetuximab in patients with advanced biliary cancer - BINGOadenocarcinoma of the biliary tract ( gallbladder, intra and/ or extrahepatic bile ducts, ampulla of Vater)
EUCTR2007-001200-20-DEMedizinische Hochschule Hannover100
已完成
2 期
A multicenter randomized phase II clinical trial with neo -adjuvant chemotherapy containing eribulin mesylate for triple negative primary breast cancer patients (Neo-Entrance study)Patients with operable primary triple-negative breast cancer without prior treatment
JPRN-UMIN000023162Japan Breast Cancer Research Group)100